AI-enabled medical devices with limited pre-market validation are more likely to be recalled after FDA clearance.
Key Details
- 1AI-enabled device recalls are more common among those lacking prospective human validation prior to FDA 510(k) clearance.
- 2Most AI medical devices are cleared without requiring prospective clinical testing.
- 3Study reviewed all U.S. recalls of AI-enabled devices between Nov. 15–30, 2024.
- 4Validation method (none, retrospective, or prospective) was a notable factor influencing recall likelihood.
- 5Recalls were categorized into errors such as diagnostic, measurement, and functional issues.
Why It Matters
These findings highlight the inadequacy of current FDA pathways to ensure AI device reliability and safety in clinical environments. For radiology professionals and developers, the results underscore the critical importance of robust validation before market approval.
Source
Health Imaging
Related News
•HealthExec
AI's Expanding Role in Healthcare and Implications for Radiology
A series of thought leaders and institutions weigh in on AI's transformative potential in healthcare, with emphasis on radiology adoption and responsible use.
•Radiology Business
Most Radiology AI Users Lack Clear Evidence of Financial ROI
Survey finds over 75% of radiology organizations using AI lack clear, quantified ROI data.
•AuntMinnie
Toronto Study: LLMs Must Cite Sources for Radiology Decision Support
University of Toronto researchers found that large language models (LLMs) such as DeepSeek V3 and GPT-4o offer promising support for radiology decision-making in pancreatic cancer when their recommendations cite guideline sources.